Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVD + Brentuximab Vedotin +/- Nivolumab in Stage I-II Hodgkin Lymphoma
NCT03233347Phase 2Active, not recruiting
- Sponsor
- Academic and Community Cancer Research United
- Start
- Oct 2017
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, brentuximab vedotin in Hodgkin lymphoma (HL), sponsored by Academic and Community Cancer Research United. Started Oct 2017; status: active, not recruiting.
02
Drugs
nivolumabbrentuximab vedotin
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT03233347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03233347.